Wellcome Trust

CARB-X published compulsory guidance on Monday to ensure that new antibacterial products brought to market by its funded companies are used responsibly and made available to people in LMICs.

The Stewardship and Access Plan Development Guide—created by the Boston University-led nonprofit and its partners, including the Access to Medicine Foundation, the Gates Foundation, the Global Antibiotic Research and Development Partnership, the Global Antimicrobial Resistance Innovation Fund, and…

The state of the hunt:

J&J’s vaccine became the first single-dose Covid-19 jab to receive EUL from the World Health Organization.
  A growing list of countries—including at least one COVAX AMC participant—suspended their rollouts of AstraZeneca’s vaccine over safety concerns.
  Monoclonal antibodies from Lilly and a separate mAb from GSK and Vir substantially cut the risk of hospitalization or death in people with mild or moderate Covid-19 at high risk of progression…

The Drugs for Neglected Diseases initiative (DNDi) and Novartis announced yesterday that they have agreed to jointly develop LXE408, a first-in-class compound discovered by Novartis, with financial support from the Wellcome Trust, as a potential new oral treatment for visceral leishmaniasis.

Under the terms of the deal, Novartis will be responsible for Phase 1 trials, regulatory submissions, and “affordable” distribution of the drug. DNDi will lead Phase 2 and 3 development, with the…

Britain’s Wellcome Trust issued a report last week saying “too many people” lack access to the healthcare interventions they need.

Wellcome attributed the problem to a lack of R&D in areas of unmet need, “varied mechanisms” for intellectual property management and pricing, and diverse regulatory approaches—all of which are exacerbated by weak health systems and inadequate healthcare financing.

The report said specific challenges for itself and other health R&D funders…

CARB-X announced this week that it is adding six organizations to its Global Accelerator Network, more than doubling the number of accelerator partners that can provide business, scientific and technical expertise and services to CARB-X-funded companies for their antibacterial research projects.

The new accelerators are Denmark’s BioInnovation Institute, the German Center for Infection Research, India’s Centre for Cellular and Molecular Platforms, the New Jersey-based Institute for…

Global health think tank Policy Cures Research released its annual G-FINDER survey results today, reporting a new high of $3.6 billion in neglected disease R&D investment made in financial year 2017, up 7 percent from the previous year.

The public sector remained the largest source of funding at $2.3 billion and generated the overall increase because of new investments by the United Kingdom, European Commission, Germany and India. The United States remained the world’s largest…

Wellcome Trust and the Boston Consulting Group released a report this week saying that, with better focus and funding, vaccines could do much more to combat antimicrobial resistance.

Using WHO’s priority pathogen list as a starting point, the researchers developed scorecards estimating vaccine health impact, probability of R&D success, and probability of uptake.

Vaccines for TB, pneumonia, gonorrhea and Shigella were estimated to provide the largest reductions in global…

biotech Kineta, Inc. announced today that it has started Phase 1 trials of its LHF-535 oral antiviral treatment for Lassa hemorrhagic fever.

Kineta expects results from its single-ascending dose study in the first quarter of 2019 and will then start a multiple-ascending dose study.

Wellcome Trust gave Kineta up to $7.2 million in 2016 to take LHF-535 through Phase 1.

Last month, the U.S. FDA added Lassa fever to its list of tropical diseases eligible for its priority review…

Australia’s Monash University announced this week that the Gates Foundation and Wellcome Trust have given its World Mosquito Program (WMP) $38 million for a further three years of work, bringing total contributions since 2010 to $134 million.

WMP is using Aedes aegypti infected with Wolbachia bacteria, which can stop dengue, chikungunya and Zika viruses from growing inside the mosquito, to mate with wild mosquitoes and decrease the population’s ability to transmit diseases.

Since…

Wellcome Trust announced this week the launch of the Surveillance and Epidemiology of Drug-resistant Infections Consortium (SEDRIC) to help countries track, share and analyze information on anti-microbial resistance.

This comes as WHO released its first Global Antimicrobial Surveillance System (GLASS) report this week, which found a widespread occurrence of antibiotic resistance worldwide and variable quality of data because of substandard surveillance in some countries.

Mentions: